Isturisa

Osilodrostat, the active ingredient in Isturisa, is a 11β-hydroxylase inhibitor presented as a tablet for oral use. It treats Cushing's disease by reducing cortisol production in patients with pituitary‑dependent hypercortisolism.

GNH USA supplies Isturisa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osilodrostat is used to manage disorders of cortisol excess, particularly Cushing's disease.

Cushing's disease (pituitary‑dependent): lowers cortisol levels and improves clinical signs. Adrenal Cushing's syndrome: suppresses excess cortisol synthesis from the adrenal gland. Ectopic ACTH‑producing tumors: reduces cortisol production when the source is non‑pituitary.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: reduced energy levels, especially during dose titration. - Headache: transient cranial discomfort. - Decreased appetite: reduced food intake leading to mild weight loss. - Dizziness: sensation of light‑headedness, often positional. - Hypertension: modest increase in blood pressure.

Serious or Rare Side Effects: - Adrenal insufficiency: signs of cortisol deficiency requiring medical attention. - Hypokalemia: low potassium levels that may cause muscle weakness. - QT interval prolongation: potential cardiac rhythm disturbance. - Severe hypertension: marked elevation in blood pressure needing urgent care.

Osilodrostat requires careful monitoring to ensure safe and effective use.

Monitor cortisol levels: adjust dose based on biochemical response. Assess blood pressure: watch for hypertension or hypotension. Evaluate electrolytes: check potassium and sodium regularly. Review hepatic function: liver enzymes should be measured periodically. Avoid abrupt discontinuation: taper under medical supervision to prevent adrenal crisis. Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Osilodrostat may interact with other medicines that affect steroid metabolism or cardiovascular function.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce osilodrostat exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase drug levels and toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: blood pressure may fall further; dose adjustment may be needed. - Diuretics that cause potassium loss: risk of hypokalemia may increase. - Oral contraceptives: cortisol reduction could affect hormonal balance; monitor efficacy.